---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-22-006505"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2022-02-24T23:59:59+00:00"
generated_at: "2026-06-27T04:40:13.877648+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Femasys appoints Dov Elefant as CFO effective Feb 28, 2022

## Summary
- Dov Elefant, former CFO of Cellectar Biosciences, named CFO of Femasys.
- Annual salary of $400,000; target bonus 40% of base salary.
- Inducement option for 100,000 shares, vesting over four years.
- Effective February 28, 2022, succeeding prior CFO arrangement.

## SEC filing metadata
- accession: 0001140361-22-006505
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2022-02-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036122006505/0001140361-22-006505-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036122006505/brhc10034387_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-22-006505
- JSON: https://secwatch.observer/filing/0001140361-22-006505.json
- Plain text: https://secwatch.observer/filing/0001140361-22-006505.txt

## Key facts
- Executive change
  Dov Elefant was appointed as Chief Financial Officer at FEMASYS INC.
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On February 24, 2022, Femasys Inc. (the “ Company ”) announced the hiring and appointment of Dov Elefant as its Chief Financial Officer, effective February 28, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1339005/000114036122006505/0001140361-22-006505-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.